Altera Biosciences

Altera Biosciences is a preclinical-stage biotechnology company that has developed a computational platform to discover and develop epigenetic medicines. Founded in 2021 by Stewart Abbot, Rinath Jeselsohn, and Frank Stegmeier, the company is backed by a partnership with Schrödinger and its platform, which integrates physics-based modeling, machine learning, and experimental validation to create small molecule therapeutics. This collaboration provides Altera with exclusive access to Schrödinger's advanced computational tools for specific epigenetic targets.

The company's primary focus is on developing drugs that target chromatin biology, which plays a crucial role in gene regulation and has been implicated in a variety of diseases, particularly cancer. By deciphering the language of gene control, Altera aims to create therapies that can modify the epigenetic landscape to treat these conditions. Its business model involves leveraging its proprietary platform to identify and advance novel drug candidates through the preclinical stages before potentially partnering with larger pharmaceutical companies for clinical development and commercialization. The company operates at the intersection of computational biology and drug discovery, targeting the oncology market.

Keywords: epigenetic medicine, computational drug discovery, preclinical biotechnology, oncology therapeutics, chromatin biology, small molecule drugs, AI in pharma, gene regulation, cancer therapies, drug development platform